BCR-ABL rearrangements in acute lymphoblastic leukaemia

Lucas, Guy; Ardern, John; Bartram, C. R.

doi:10.1016/0140-6736(91)93241-z

Cited by 6 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, they are all chimeras whose discoveries have benefited significantly from transcriptome sequencing [28]. The most-well-known gene fusion is undoubtedly BCR-ABL, generated from t(9;22) in chronic myelogenous leukemia (CML) [36] and in acute lymphoblastic leukemia (ALL) [37]. BCR-ABL inhibitors, such as Imatinib and Dasatinib, are already widely applied in clinical practice [38].…”

Section: Gene Fusionmentioning

confidence: 99%

Chimeric RNAs Discovered by RNA Sequencing and Their Roles in Cancer and Rare Genetic Diseases

Sun

2022

Genes

View full text Add to dashboard Cite

Chimeric RNAs are transcripts that are generated by gene fusion and intergenic splicing events, thus comprising nucleotide sequences from different parental genes. In the past, Northern blot analysis and RT-PCR were used to detect chimeric RNAs. However, they are low-throughput and can be time-consuming, labor-intensive, and cost-prohibitive. With the development of RNA-seq and transcriptome analyses over the past decade, the number of chimeric RNAs in cancer as well as in rare inherited diseases has dramatically increased. Chimeric RNAs may be potential diagnostic biomarkers when they are specifically expressed in cancerous cells and/or tissues. Some chimeric RNAs can also play a role in cell proliferation and cancer development, acting as tools for cancer prognosis, and revealing new insights into the cell origin of tumors. Due to their abilities to characterize a whole transcriptome with a high sequencing depth and intergenically identify spliced chimeric RNAs produced with the absence of chromosomal rearrangement, RNA sequencing has not only enhanced our ability to diagnose genetic diseases, but also provided us with a deeper understanding of these diseases. Here, we reviewed the mechanisms of chimeric RNA formation and the utility of RNA sequencing for discovering chimeric RNAs in several types of cancer and rare inherited diseases. We also discussed the diagnostic, prognostic, and therapeutic values of chimeric RNAs.

show abstract

Section: Gene Fusionmentioning

confidence: 99%

Chimeric RNAs Discovered by RNA Sequencing and Their Roles in Cancer and Rare Genetic Diseases

Sun

2022

Genes

View full text Add to dashboard Cite

show abstract

“…It is formed by a reciprocal chromosomal translocation generating a fusion protein with a constitutively active kinase domain that allows it to signal all the time by activating cancer-promoting signaling pathways. 38 Afterward, other gene fusions were soon identified in solid tumors. For instance, the oncogenic EML4–ALK fusion, resulting from the inversion of chromosome 2, on which both genes are located, was described in anaplastic lymphoma, and later in patients with non-small cell lung cancer.…”

Section: Gene Fusions Involving Pcg: Highlights In Cancermentioning

confidence: 99%

Breaking paradigms: Long non-coding RNAs forming gene fusions with potential implications in cancer

Sánchez-Marín,

Silva-Cázares,

Porras-Reyes

et al. 2024

Genes & Diseases

View full text Add to dashboard Cite

“…The BCR–ABL1 , the first oncogenic fusion gene ever identified, is formed by a reciprocal chromosomal translocation. BCR–ABL1 , which is generated from translocation t(9; 22) (q34; q11), is characteristic of CML [ 9 ] and also found in acute lymphoid leukemia (ALL) [ 57 ] and acute myelogenous leukemia (AML) [ 58 ]. The fusion gene BCR–ABL1 has a constitutive tyrosine kinase activity, which leads to sustained stimulation on proliferation of cancer cells [ 8 ].…”

Section: Biosynthesis Patterns Of Fusion Genes and Rnasmentioning

confidence: 99%

Fusion Genes and RNAs in Cancer Development

Taniue

Akimitsu

2021

ncRNA

View full text Add to dashboard Cite

Fusion RNAs are a hallmark of some cancers. They result either from chromosomal rearrangements or from splicing mechanisms that are non-chromosomal rearrangements. Chromosomal rearrangements that result in gene fusions are particularly prevalent in sarcomas and hematopoietic malignancies; they are also common in solid tumors. The splicing process can also give rise to more complex RNA patterns in cells. Gene fusions frequently affect tyrosine kinases, chromatin regulators, or transcription factors, and can cause constitutive activation, enhancement of downstream signaling, and tumor development, as major drivers of oncogenesis. In addition, some fusion RNAs have been shown to function as noncoding RNAs and to affect cancer progression. Fusion genes and RNAs will therefore become increasingly important as diagnostic and therapeutic targets for cancer development. Here, we discuss the function, biogenesis, detection, clinical relevance, and therapeutic implications of oncogenic fusion genes and RNAs in cancer development. Further understanding the molecular mechanisms that regulate how fusion RNAs form in cancers is critical to the development of therapeutic strategies against tumorigenesis.

show abstract

BCR-ABL rearrangements in acute lymphoblastic leukaemia

Cited by 6 publications

References 1 publication

Chimeric RNAs Discovered by RNA Sequencing and Their Roles in Cancer and Rare Genetic Diseases

Chimeric RNAs Discovered by RNA Sequencing and Their Roles in Cancer and Rare Genetic Diseases

Breaking paradigms: Long non-coding RNAs forming gene fusions with potential implications in cancer

Fusion Genes and RNAs in Cancer Development

Contact Info

Product

Resources

About